Showing results (71-80 of 109) with videos related to
Sort By:
Pageof 11
JAMA Network Open|January 24, 2025
18F-Fluorodeoxyglucose Uptake in PDGFRA-Mutant Gastrointestinal Stromal TumorsMaria Concetta Nigro, Andrea Marchetti, Elena Rosa Fumagalli, et al.JAMA Oncology|June 4, 2026
PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression: A Systematic Review and Meta-AnalysisAlessandro Di Federico, Samuele Compagno, Francesco Mantuano, et al.JAMA Oncology|May 23, 2024
Body Composition in Advanced Non-Small Cell Lung Cancer Treated With ImmunotherapyTafadzwa L Chaunzwa, Jack M Qian, Qin Li, et al.Nature Communications|July 15, 2023
Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLCJoao V Alessi, Biagio Ricciuti, Xinan Wang, et al.JCO Precision Oncology|November 16, 2023
Amplification of Wild-Type <i>RET</i> Represents a Novel Molecular Subtype of Several Cancer Types With Clinical Response to SelpercatinibMalini M Gandhi, Biagio Ricciuti, Guilherme Harada, et al.Journal for Immunotherapy of Cancer|November 1, 2023
Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancerJoao V Alessi, Adam Price, Allison L Richards, et al.Translational Lung Cancer Research|August 13, 2025
Upfront osimertinib and as sequential therapy in patients with <i>EGFR</i>-mutant non-small cell lung cancer (NSCLC): benefit across patients groups in a real-world retrospective cohort-the smile studyEdouard Auclin, Pauline Du Rusquec, Victor Albarran-Artahona, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2024
Transcriptional Phenocopies of Deleterious KEAP1 Mutations Correlate with Survival Outcomes in Lung Cancer Treated with ImmunotherapyStefano Scalera, Biagio Ricciuti, Daniele Marinelli, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2025
MAPK Pathway-Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT TrialFederico Cappuzzo, Biagio Ricciuti, Angelo Delmonte, et al.Journal for Immunotherapy of Cancer|July 24, 2023
Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort studyArielle Elkrief, Joao M Victor Alessi, Biagio Ricciuti, et al.Pageof 11